DCx Biotherapeutics
The startup is developing precision drug conjugates that utilize targeted delivery mechanisms to enhance therapeutic efficacy while minimizing toxicity compared to traditional antimitotic and topoisomerase-inhibiting antibody-drug conjugates (ADCs). This approach aims to improve patient outcomes in cancer treatment by reducing adverse side effects associated with conventional therapies.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing precision drug conjugates that utilize targeted delivery mechanisms to enhance therapeutic efficacy while minimizing toxicity compared to traditional antimitotic and topoisomerase-inhibiting antibody-drug conjugates (ADCs). This approach aims to improve patient outcomes in cancer treatment by reducing adverse side effects associated with conventional therapies.